Menu Search
Equities

Shanghai ZJ Bio-Tech Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
688317:SHH

Shanghai ZJ Bio-Tech Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)19.82
  • Today's Change-0.69 / -3.36%
  • Shares traded2.92m
  • 1 Year change+15.10%
  • Beta1.0566
Data delayed at least 15 minutes, as of Mar 03 2026.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Shanghai ZJ Bio-Tech Co Ltd had revenues fall -34.88% from 274.33m to 178.65m, though the company grew net income from a loss of 136.86m to a smaller loss of 127.46m.
Gross margin44.26%
Net profit margin-109.37%
Operating margin-124.16%
Return on assets-3.76%
Return on equity-4.01%
Return on investment-3.90%
More ▼

Cash flow in CNYView more

In 2024, Shanghai ZJ Bio-Tech Co Ltd did not generate a significant amount of cash. However, the company earned 77.59m from its operations for a Cash Flow Margin of 43.43%. In addition the company used 19.42m on investing activities and also paid 58.72m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share17.66
Tangible book value per share17.60
More ▼

Balance sheet in CNYView more

Shanghai ZJ Bio-Tech Co Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.71% of the market capitalization can be attributed to its 2.78bn and debt could be paid in full if management chose.
Current ratio23.06
Quick ratio22.65
Total debt/total equity0.0591
Total debt/total capital0.0558
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items increased 5.93%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		28.73
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.